Nav: Home

Standard dosage for one lung cancer treatment may be too high

June 06, 2017

A new study published in the Journal of the National Cancer Institute indicates that the customary pembrolizumab dose for treatment of metastatic non-small cell lung cancer may be higher than is needed for effective treatment.

In October 2016, pembrolizumab became the new standard of care for firstline treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death ligand 1 in at least 50% of cells.

The standard dosage for pembrolizumab was based the KEYNOTE 024 trial. The dosage used in the trial was 200 mg for all patients (fixed dosing) every three weeks. As a result, this was the dose recommended by the Food and Drug Administration. Multiple studies have demonstrated equivalent efficacy with lower weight-based doses (personalized dosing), however. The objective of this study was to compare the economic impact of using personalized dosing (2 mg/kg) vs fixed dosing (200 mg).

Researchers suspected that using the FDA-approved dose of 200 mg for all patients may be an unnecessarily high dose, given that the average weight in the United States is 82 kg. In an era of value-based cancer care, avoidance of drug wastage is of paramount importance. If dosed at 2 mg/kg, an appropriate dose for the average American adult would be 164 mg.

Researchers performed a budget impact analysis to compare fixed dosing with personalized. They calculated the target population and weight of patients who would be treated with pembrolizumab annually. Using survival curves they estimated the mean number of cycles that patients would receive. Using the Medicare average sales price, researchers calculated the difference in cost between personalized and fixed dosing.

The results of the study indicated that the total annual cost of pembrolizumab with fixed dosing is $3.4 billion, but with personalized dosing it would be $2.6 billion. The use of personalized dosing would likely lead to a 24.0% annual savings, some $825 million.

Using dosing manipulations such as that described for pembrolizumab could be one way for payers to improve value within the current system. Although some cancer drug prices have increased in recent years, the price of pembrolizumab has remained fairly constant every quarter for the past six quarters at around $46 per mg.
-end-
The paper "A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer" is available at: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djx057

Direct correspondence to:

Daniel A. Goldstein, MD
Davidoff Cancer Center
Rabin Medical Center, Ze'ev Jabotinsky Rd 39, Petah Tikva, 4941492
ISRAEL
dgolds8@emory.edu

To request a copy of the study, please contact: Daniel Luzer- daniel.luzer@oup.com

The Journal of the National Cancer Institute publishes peer-reviewed original research from around the world and is internationally acclaimed as the source for the most up-to-date news and information from the rapidly changing fields of cancer research and treatment. For the past several years, the JNCI has been ranked as one of the most-cited original-research cancer journals by the Institute of Scientific Information in its annual Journal Citation Reports.

Sharing on social media? Find Oxford Journals online at @OxfordJournals

Oxford University Press USA

Related Pembrolizumab Articles:

Tumor PD-L2 expression may predict patient response to anti-PD-1 immunotherapy
PD-L2 protein expression in human tumors was associated with clinical response to pembrolizumab (Keytruda), an anti-PD-1 immunotherapy, independent of PD-L1 expression, in patients with head and neck squamous cell carcinoma (HNSCC).
Flaws in a tumor's genetic mending kit drive treatment response to immunotherapy
In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called 'mismatch repair' genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda).
Genetic mutations predict patient response to immunotherapy
Results of a new clinical study establish particular genetic defects in tumors as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade.
Standard dosage for one lung cancer treatment may be too high
A new study published in the Journal of the National Cancer Institute indicates that the customary pembrolizumab dose for treatment of metastatic non-small cell lung cancer may be higher than is needed for effective treatment.
Immunotherapy drug effective for metastatic triple negative breast cancer
The immunotherapy drug, Pembrolizumab, is effective in shrinking tumors among metastatic triple negative breast cancer patients as found in a clinical trial led by NYU Langone's Perlmutter Cancer Center.
Penn studies show hope for multiple cancers with pembrolizumab combination therapies
The combination of pembrolizumab and the checkpoint inhibitor known as epacadostat is leading to promising responses and is generally well tolerated in patients with triple-negative breast cancer, non-small cell lung cancer, squamous cell cancer of the head and neck, and several other cancers, according to researchers from the Abramson Cancer Center of the University of Pennsylvania.
Pembrolizumab in non-small cell lung cancer: Hint of considerable added benefit
Good study design allows identification of the relevant subpopulation, in which prolonged overall survival notably outweighs disadvantages in some side effects.
White blood cell count predicts response to lung cancer immunotherapy
White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).
New imaging method may predict immunotherapy response early
A noninvasive PET imaging method that measures granzyme B, a protein released by immune cells to kill cancer cells, was able to distinguish mouse and human tumors that responded to immune checkpoint inhibitors from those that did not respond early in the course of treatment.
Annual flu jab may pose greater risk for lung cancer patients under immunotherapy
Lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors may be at increased risk of adverse events after receiving the seasonal influenza vaccination, according to the first study measuring this effect.

Related Pembrolizumab Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...